Search Results - "Mathias, Anita A"

Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir by Kirby, Brian J., Symonds, William T., Kearney, Brian P., Mathias, Anita A.

“…Sofosbuvir (SOVALDI ® ), a potent, once-daily, orally administered nucleotide analog prodrug inhibitor of the hepatitis C virus (HCV) NS5B polymerase is…”
Get full text

Clinical Pharmacokinetic and Pharmacodynamic Profile of the HIV Integrase Inhibitor Elvitegravir by Ramanathan, Srinivasan, Mathias, Anita A., German, Polina, Kearney, Brian P.

“…Elvitegravir is a potent, boosted, once-daily, HIV integrase inhibitor with antiviral activity against wild-type and drug-resistant strains of HIV. Because…”
Get full text

Pharmacokinetics and Safety of Indinavir in Human Immunodeficiency Virus-Infected Pregnant Women by UNADKAT, Jashvant D, WARA, Diane W, MOFENSON, Lynne M, SMITH, Elizabeth, DEUTSCH, Paul, KAISER, Kathleen A, TUOMALA, Ruth E, HUGHES, Michael D, MATHIAS, Anita A, HOLLAND, Diane T, PAUL, Mary E, CONNOR, James, HUANG, Sharon, NGUYEN, Bach-Yen, WATTS, D. Heather

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Changes in pharmacokinetics of anti-HIV protease inhibitors during pregnancy: the role of CYP3A and P-glycoprotein by Mathias, Anita A, Maggio-Price, Lillian, Lai, Yurong, Gupta, Anshul, Unadkat, Jashvant D

“…Human immunodeficiency virus (HIV)-infected women have reduced exposure [area under the curve (AUC)] to anti-HIV protease inhibitors [e.g., nelfinavir (NFV)]…”
Get more information

Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/ tenofovir df in the initial treatment of HIV infection by ELION, Richard, COHEN, Calvin, GATHE, Joseph, SHALIT, Peter, HAWKINS, Trevor, LIU, Hui C, MATHIAS, Anita A, CHUCK, Steven L, KEARNEY, Brian P, WARREN, David R

“…To assess efficacy and safety of cobicistat versus ritonavir as pharmacoenhancers for atazanavir when administered with emtricitabine/tenofovir df as initial…”
Get full text

P-glycoprotein and breast cancer resistance protein expression in human placentae of various gestational ages by Mathias, Anita A, Hitti, Jane, Unadkat, Jashvant D

“…Placental efflux transporters such as P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) protect the developing fetus from exposure to…”
Get more information

Bioequivalence of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen by Mathias, Anita A, Hinkle, John, Menning, Mark, Hui, James, Kaul, Sanjeev, Kearney, Brian P

“…OBJECTIVE:Efavirenz (EFV; 600 mg), emtricitabine (FTC; 200 mg) and tenofovir disoproxil fumarate (TDF; 300 mg) are preferred agents for treatment of HIV-1…”
Get full text

Effect of Ritonavir-Boosted Tipranavir or Darunavir on the Steady-State Pharmacokinetics of Elvitegravir by Mathias, Anita A, Hinkle, John, Shen, Gong, Enejosa, Jeff, Piliero, Peter J, Sekar, Vanitha, Mack, Rebecca, Tomaka, Frank, Kearney, Brian P

“…OBJECTIVE:Elvitegravir (EVG) is in phase 3 development in combination with ritonavir (RTV)-boosted protease inhibitors in treatment-experienced, HIV-infected…”
Get full text

Disposition of anti -HIV protease inhibitors in pregnancy by Mathias, Anita A

“…Maternal exposure (AUC) to anti-HIV protease inhibitors (Pis) (e.g. saquinavir) is significantly reduced (by 75%) in pregnant HIV-infected women when compared…”
Get full text